TY - JOUR
T1 - Molecular cloning and characterization of a second human cysteinyl leukotriene receptor
T2 - Discovery of a subtype selective agonist
AU - Nothacker, Hans Peter
AU - Wang, Zhiwei
AU - Zhu, Yuhong
AU - Reinscheid, Rainer K.
AU - Lin, Steven H.S.
AU - Civelli, Olivier
PY - 2000
Y1 - 2000
N2 - The cysteinyl leukotrienes (CysLTs) are potent biological mediators in the pathophysiology of inflammatory diseases, in particular of airway obstruction in asthma. Pharmacological studies have suggested the existence of at least two types of CysLT receptors, designated CysLT1 and CysLT2. The CysLT1 receptor has been cloned recently. Here we report the molecular cloning, expression, localization, and functional characterization of a human G protein-coupled receptor that has the expected characteristics of a CysLT2 receptor. This new receptor is selectively activated by nanomolar concentrations of CysLTs with a rank order potency of LTC4 = LTD4 >> LTE4. The leukotriene analog BAY u9773, reported to be a dual CysLT1/CysLT2 antagonist, was found to be an antagonist at CysLT1 sites but acted as a partial agonist at this new receptor. The structurally different CysLT1 receptor-selective antagonists zafirlukast, montelukast, and MK-571 did not inhibit the agonist-mediated calcium mobilization of CysLT2 receptors at physiological concentrations. Localization studies indicate highest expression of CysLT2 receptors in adrenal glands, heart, and placenta; moderate levels in spleen, peripheral blood leukocytes, and lymph nodes; and low levels in the central nervous system and pituitary. The human CysLT2 receptor gene is located on chromosome 13q14.12-21.1. The new receptor exhibits all characteristics of the thus far poorly defined CysLT2 receptor. Moreover, we have identified BAY u9773 as a CysLT2 selective agonist, which could prove to be of immediate use in understanding the functional roles of the CysLT2 receptor.
AB - The cysteinyl leukotrienes (CysLTs) are potent biological mediators in the pathophysiology of inflammatory diseases, in particular of airway obstruction in asthma. Pharmacological studies have suggested the existence of at least two types of CysLT receptors, designated CysLT1 and CysLT2. The CysLT1 receptor has been cloned recently. Here we report the molecular cloning, expression, localization, and functional characterization of a human G protein-coupled receptor that has the expected characteristics of a CysLT2 receptor. This new receptor is selectively activated by nanomolar concentrations of CysLTs with a rank order potency of LTC4 = LTD4 >> LTE4. The leukotriene analog BAY u9773, reported to be a dual CysLT1/CysLT2 antagonist, was found to be an antagonist at CysLT1 sites but acted as a partial agonist at this new receptor. The structurally different CysLT1 receptor-selective antagonists zafirlukast, montelukast, and MK-571 did not inhibit the agonist-mediated calcium mobilization of CysLT2 receptors at physiological concentrations. Localization studies indicate highest expression of CysLT2 receptors in adrenal glands, heart, and placenta; moderate levels in spleen, peripheral blood leukocytes, and lymph nodes; and low levels in the central nervous system and pituitary. The human CysLT2 receptor gene is located on chromosome 13q14.12-21.1. The new receptor exhibits all characteristics of the thus far poorly defined CysLT2 receptor. Moreover, we have identified BAY u9773 as a CysLT2 selective agonist, which could prove to be of immediate use in understanding the functional roles of the CysLT2 receptor.
UR - http://www.scopus.com/inward/record.url?scp=0033664314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033664314&partnerID=8YFLogxK
U2 - 10.1124/mol.58.6.1601
DO - 10.1124/mol.58.6.1601
M3 - Article
C2 - 11093801
AN - SCOPUS:0033664314
SN - 0026-895X
VL - 58
SP - 1601
EP - 1608
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 6
ER -